相关实验视频
Updated: May 24, 2025

16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
20.1K
基因表达与雌激素受体阳性乳腺癌中的内分泌治疗耐药性相关
Veronica Jones1, Hongwei Holly Yin2, Yate-Ching Yuan3
1Department of Surgery, City of Hope, 1500 E Duarte Rd, Duarte, CA, 91010, USA. vjones@coh.org.
Scientific reports
|February 28, 2025
概括
这项研究确定了EZH2和WNT11等关键基因,这些基因与接受内分泌治疗的雌激素受体阳性乳腺癌患者的复发有关. 这些发现可能会导致新的生物标志物克服治疗耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 雌激素受体阳性乳腺癌 (ER+BC) 复发发生在20-40%的患者中,尽管内分泌治疗 (ET).
- 在ET期间的复发意味着内分泌治疗耐药性,这是一个重要的临床挑战.
- 确定ET抗性的分子驱动因素对于改善患者的治疗结果至关重要.
研究的目的:
- 确定与ER+BC中ET抵抗相关的差异表达基因 (DEGs).
- 为了探索与复发有关的PAM50分子亚型之间的基因表达差异.
- 发现潜在的生物标志物来预测和克服ET抵抗.
主要方法:
- 分析了79名ER+BC患者的80个瘤样本,这些患者接受ET治疗.
- 利用NanoString技术进行基因表达分析.
- 与复发状态和PAM50亚型相关的基因表达.
主要成果:
- 在复发瘤中确定了关键上调的DEGs:EZH2,WNT11,ITGB6和TOP2A.
- 确定了关键的下调 DEG:SNAI2,ITPR1,CD10,PTEN,VRD 和 WNT5A. 这些 DEG 已被下调.
- EZH2和TOP2A与扩散相关;WNT11和ITGB6与复发有独立的关联.
结论:
- EZH2,WNT11,ITGB6和TOP2A都与ET抗性和ER+BC的复发有关.
- WNT11和ITGB6可以作为预测复发风险的新生物标志物.
- 这些发现为克服ET耐药性和改善ER+BC患者的存活率提供了潜在的治疗点.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Internal Receptors
69.2K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.2K

